arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces it has successfully generated potent antibody antagonists of Nav1.7, using its proprietary SIMPLE Antibody™ technology.
arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces it has successfully generated potent antibody antagonists of Nav1.7, using its proprietary SIMPLE Antibody™ technology.